TP53 and ovarian cancer: In HGSOC, mutations were not significantly associated with FIGO stage III or IV, tumor grading (G2 or G3), or tumor residue after PDS (RD = 0 or RD < 1; Table 2), except for platinum-sensitivity: platinum-refractory ovarian cancer was significantly associated with presence of a mutation in APC (p = 0.0001, Table 2), which was detected in one patient (#275), that had also a concurrent mutation in TP53 (Figure 1a).